Mini Review

Published on 24 May 2023

Drug discovery and development: introduction to the general public and patient groups

in Technologies and Strategies to Enable Drug Discovery

Natesh Singh
Philippe Vayer
Shivalika Tanwar
Jean-Luc Poyet
Katya Tsaioun
Bruno O. Villoutreix

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1201419

88,197 views
31 citations

Review

Published on 10 May 2023

The critical role of mode of action studies in kinetoplastid drug discovery

in Anti-Infective Agents

Alan H. Fairlamb
Susan Wyllie

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1185679

2,438 views
3 citations

Original Research

Published on 09 May 2023

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

in Anti-Cancer Drugs

Irene Tang
Lauren Schwimmer
Shenda Gu
Wei Wei Prior
Hieu Van Tran
Allan Chan
Anna McClain
Christopher C. Fraser
Chunyan Sun
Meimei Si

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1182146

3,472 views
1 citation

Editorial

Published on 27 Feb 2023

Editorial: Development/repurposing of drugs to tackle the multiple variants of SARS-CoV-2

in Anti-Infective Agents

Dinorah Gambino

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1157688

901 views
1 citation

Brief Research Report

Published on 21 Feb 2023

Numaswitch, a biochemical platform for the efficient production of disulfide-rich pepteins

in Neurological Drugs

Bach-Ngan Nguyen
Florian Tieves
Florian G. Neusius
Hansjörg Götzke
Lutz Schmitt
Christian Schwarz

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1082058

2,323 views
1 citation

Original Research

Published on 10 Feb 2023

HMM-based profiling identifies the binding to divalent cations and nucleotides as common denominators of suramin targets

in Anti-Infective Agents

Dennis A. Hauser
Pascal Mäser

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1112992

1,339 views

Original Research

Published on 08 Feb 2023

Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort

in Cardiovascular and Hematologic Drugs

Alex Pu
Gautam Ramani
Yi-Ju Chen
James A. Perry
Charles C. Hong

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1127736

3,016 views
5 citations

Original Research

Published on 20 Jan 2023

In silico identification of potential inhibitors of acyl carrier protein reductase and acetyl CoA carboxylase of Plasmodium falciparum in antimalarial therapy

in In silico Methods and Artificial Intelligence for Drug Discovery

Elliasu Y. Salifu
James Abugri
Issahaku A. Rashid
Festus Osei
Joseph Atia Ayariga

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1087008

2,448 views
4 citations

Original Research

Published on 12 Jan 2023

The use of cyclic peptide antigens to generate LRP8 specific antibodies

in Technologies and Strategies to Enable Drug Discovery

Maria A. Argiriadi
Kangwen Deng
David Egan
Lei Gao
Farid Gizatullin
John Harlan
Denise Karaoglu Hanzatian
Wei Qiu
Ruth Villanueva
Andrew Goodearl

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1093153

2,132 views
2 citations

Brief Research Report

Published on 09 Jan 2023

Determination of nucleoside DOT1L inhibitors’ residence times by τRAMD simulations

in In silico Methods and Artificial Intelligence for Drug Discovery

Carlos D. Flores-León
Luis Fernando Colorado-Pablo
Miguel Á. Santos-Contreras
Rodrigo Aguayo-Ortiz

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1083198

1,550 views
1 citation

Brief Research Report

Published on 05 Jan 2023

Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease

in Anti-Infective Agents

Denis N. Prada Gori
Santiago Ruatta
Martín Fló
Lucas N. Alberca
Carolina L. Bellera
Soonju Park
Jinyeong Heo
Honggun Lee
Kyu-Ho Paul Park
Otto Pritsch

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1082065

2,434 views
2 citations

Editorial

Published on 05 Jan 2023

Editorial: Insights in silico methods and artificial intelligence for drug discovery: 2022

in In silico Methods and Artificial Intelligence for Drug Discovery

José L. Medina-Franco

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1126955

1,753 views
1 citation

Original Research

Published on 23 Dec 2022

Discovery of novel spike/ACE2 inhibitory macrocycles using in silico reinforcement learning

in In silico Methods and Artificial Intelligence for Drug Discovery

Lev Shapira
Shaul Lerner
Guila Assayag
Alexandra Vardi
Dikla Haham
Gideon Bar
Vicky Fidelsky Kozokaro
Maayan Elias Robicsek
Immanuel Lerner
Amit Michaeli

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1085701

1,347 views
2 citations

Methods

Published on 19 Dec 2022

Enhanced utility of AI/ML methods during lead optimization by inclusion of 3D ligand information

in In silico Methods and Artificial Intelligence for Drug Discovery

Leo S. Bleicher
Ton van Daelen
J. Dana Honeycutt
Moises Hassan
Jayaraman Chandrasekhar
William Shirley
Vickie Tsui
Uli Schmitz

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1074797

4,799 views
4 citations

Review

Published on 15 Dec 2022

Novel and emerging therapies in pulmonary arterial hypertension

in Cardiovascular and Hematologic Drugs

Steven J. Cassady
Danielle Soldin
Gautam V. Ramani

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1022971

8,158 views
3 citations

Original Research

Published on 12 Dec 2022

In silico mapping of the dynamic interactions and structure-activity relationship of flavonoid compounds against the immune checkpoint programmed-cell death 1 pathway

in In silico Methods and Artificial Intelligence for Drug Discovery

Geraldo Rodrigues Sartori
Aline de Oliveira Albuquerque
Andrielly Henriques Santos-Costa
Luca Milério Andrade
Diego da Silva Almeida
Eduardo Menezes Gaieta
Jean Vieira Sampaio
Vitória Taiana de Melo Lima Albuquerque
João Hermínio Martins Da Silva

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1032587

3,016 views
4 citations

Navigation group

Articles

Drug discovery and development: introduction to the general public and patient groups

The critical role of mode of action studies in kinetoplastid drug discovery

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

Editorial: Development/repurposing of drugs to tackle the multiple variants of SARS-CoV-2

Numaswitch, a biochemical platform for the efficient production of disulfide-rich pepteins

HMM-based profiling identifies the binding to divalent cations and nucleotides as common denominators of suramin targets

Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort

In silico identification of potential inhibitors of acyl carrier protein reductase and acetyl CoA carboxylase of Plasmodium falciparum in antimalarial therapy

The use of cyclic peptide antigens to generate LRP8 specific antibodies

Determination of nucleoside DOT1L inhibitors’ residence times by τRAMD simulations

Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease

Editorial: Insights in silico methods and artificial intelligence for drug discovery: 2022

Discovery of novel spike/ACE2 inhibitory macrocycles using in silico reinforcement learning

Enhanced utility of AI/ML methods during lead optimization by inclusion of 3D ligand information

Novel and emerging therapies in pulmonary arterial hypertension

In silico mapping of the dynamic interactions and structure-activity relationship of flavonoid compounds against the immune checkpoint programmed-cell death 1 pathway